Humanin: The Complete Guide

Overview

Humanin (HN) is a 24-amino-acid peptide encoded by mitochondrial DNA — specifically the MT-RNR2 gene within the 16S ribosomal RNA region. It was first identified in 2001 by Nishimoto and colleagues during a functional screen for genes that could protect neurons from amyloid-beta (Aβ) toxicity, the protein fragment implicated in Alzheimer's disease pathology (Hashimoto et al., 2001).

Humanin belongs to a class of molecules known as mitochondria-derived peptides (MDPs) — small bioactive peptides encoded within the mitochondrial genome that function as signaling molecules. It was the first MDP to be discovered, and its identification opened a new field of research into how mitochondria communicate with the rest of the cell and the body through peptide-based signaling. Other MDPs discovered subsequently include MOTS-c and the small humanin-like peptides (SHLPs 1–6) (Lee et al., 2013).

The primary characteristic of humanin is its cytoprotective activity — the ability to protect cells from death. In preclinical models, humanin has demonstrated protective effects against apoptosis (programmed cell death) triggered by a range of insults including amyloid-beta toxicity, oxidative stress, serum starvation, and various chemical stressors. These effects have been observed in neuronal cells, cardiac cells, pancreatic beta cells, and other tissue types (Yen et al., 2013).

Beyond direct cytoprotection, humanin has been linked to broader biological processes relevant to aging. Circulating humanin levels decline with age in both humans and animal models. Higher humanin levels have been associated with longevity in observational studies, and humanin administration has improved metabolic parameters, reduced inflammation, and extended healthspan in animal models (Muzumdar et al., 2009).

Humanin remains entirely in the preclinical research stage. No human intervention trials have been completed. No clinical applications have been validated through controlled trials. All available data comes from in vitro (cell culture), animal models, and observational human studies measuring endogenous humanin levels. It is available only as a research chemical and is not approved for human therapeutic use by any regulatory authority.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

Receptor Binding

Humanin interacts with at least two known receptor systems:

• FPRL1/FPR2 (Formyl Peptide Receptor Like-1): Humanin binds to FPRL1, a G-protein coupled receptor involved in inflammatory regulation and immune cell signaling. This interaction mediates some of humanin's neuroprotective and anti-inflammatory effects (Ying et al., 2004).
• Trimeric receptor complex (CNTFR/WSX-1/gp130): Humanin binds to a heterotrimeric receptor composed of ciliary neurotrophic factor receptor (CNTFR), WSX-1 (IL-27 receptor alpha), and gp130 (glycoprotein 130). Activation of this complex triggers downstream JAK-STAT signaling, particularly STAT3 phosphorylation, which drives anti-apoptotic gene expression (Hashimoto et al., 2009).

Intracellular Anti-Apoptotic Mechanisms

Humanin's core function — preventing cell death — operates through several intracellular pathways:

• BAX inhibition: Humanin directly binds to BAX (BCL-2 Associated X protein), a pro-apoptotic protein that triggers mitochondrial membrane permeabilization and cytochrome c release. By sequestering BAX, humanin prevents the mitochondrial apoptotic cascade (Guo et al., 2003).
• IGFBP-3 interaction: Humanin binds to insulin-like growth factor binding protein 3 (IGFBP-3), which independently promotes apoptosis. By neutralizing IGFBP-3's pro-apoptotic activity, humanin provides an additional layer of cell survival signaling (Ikonen et al., 2003).
• STAT3 activation: Through the trimeric receptor complex, humanin activates STAT3, a transcription factor that upregulates anti-apoptotic genes including BCL-2 and MCL-1, promoting cell survival (Hashimoto et al., 2009).
• ERK1/2 pathway: Humanin activates extracellular signal-regulated kinases (ERK1/2), promoting cell survival and proliferation signaling (Yen et al., 2013).

Mitochondrial Retrograde Signaling

Humanin represents a paradigm shift in understanding mitochondrial biology. Traditionally, mitochondria were viewed primarily as energy-producing organelles receiving instructions from nuclear DNA. Humanin's discovery revealed that mitochondria also send signals outward — a concept called retrograde signaling. Humanin is transcribed from mitochondrial DNA, translated (likely within the mitochondria or cytoplasm), and then acts as a local and systemic signaling molecule (Lee et al., 2013).

Circulating humanin has been detected in human plasma, cerebrospinal fluid, and seminal fluid, indicating that it functions as a secreted peptide with endocrine-like activity — not merely an intracellular protein. This systemic presence allows mitochondria in one tissue to communicate stress or protective signals to distant organs (Yen et al., 2013).

Metabolic Effects

Humanin modulates metabolic signaling through several mechanisms:

• Insulin sensitization: Humanin improves insulin sensitivity in animal models of obesity and diabetes, partly through AMPK activation and improved mitochondrial function in insulin-responsive tissues (Muzumdar et al., 2009).
• Central metabolic regulation: Intracerebroventricular administration of humanin in rodents reduces food intake and improves glucose homeostasis, suggesting central nervous system-mediated metabolic effects (Muzumdar et al., 2009).
• GH/IGF-1 axis interaction: Humanin's binding to IGFBP-3 places it at the intersection of the growth hormone / insulin-like growth factor axis — a pathway centrally involved in aging and longevity (Ikonen et al., 2003).

The HNG Analog

A key synthetic variant of humanin is HNG ([Gly14]-Humanin, also called S14G-Humanin), in which the serine at position 14 is replaced with glycine. This single amino acid substitution increases potency approximately 1,000-fold compared to native humanin in cell-based neuroprotection assays. HNG is the most commonly used analog in preclinical research and is the form most likely to be encountered as a research chemical (Hashimoto et al., 2001).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Neurodegeneration and Neuroprotection

Neuroprotection was the original context for humanin's discovery and remains its most extensively studied application.

• Alzheimer's disease models: Humanin and its analog HNG protected neurons from amyloid-beta (Aβ)-induced toxicity in cell culture — the finding that led to humanin's discovery. In transgenic Alzheimer's mouse models (3xTg-AD), HNG administration reduced amyloid plaque burden, decreased tau hyperphosphorylation, and improved cognitive performance in maze-based behavioral tests (Tajima et al., 2005; Niikura et al., 2011).
• Amyloid-beta binding: Humanin has been shown to directly bind to Aβ fibrils and oligomers, potentially reducing their neurotoxicity through direct sequestration in addition to its receptor-mediated cytoprotective effects (Niikura et al., 2011).
• Prion-related neurodegeneration: HNG protected against neurotoxicity induced by prion protein fragments in cell culture models (Yen et al., 2013).
• Stroke / cerebral ischemia: In rodent models of middle cerebral artery occlusion (MCAO), humanin reduced infarct volume and improved neurological outcomes, suggesting potential neuroprotective activity in ischemic brain injury (Yen et al., 2013).

Cardiovascular Research

• Cardiac ischemia-reperfusion: Humanin reduced myocardial infarct size in rodent models of cardiac ischemia-reperfusion injury. The protective effect was associated with reduced apoptosis of cardiomyocytes, decreased oxidative stress, and improved left ventricular function (Muzumdar et al., 2010).
• Atherosclerosis: In ApoE-knockout mice (a standard atherosclerosis model), humanin administration reduced atherosclerotic plaque formation, decreased vascular inflammation, and improved endothelial function (Oh et al., 2011).
• Endothelial protection: Humanin protected endothelial cells from oxidative stress-induced apoptosis in cell culture, with effects mediated through AMPK activation and improved mitochondrial function (Yen et al., 2013).

Metabolic and Diabetes Research

• Insulin resistance: In high-fat-diet-induced obese mice, humanin administration improved insulin sensitivity, reduced hepatic glucose output, and improved glucose tolerance. These effects were mediated partly through hypothalamic signaling and peripheral AMPK activation (Muzumdar et al., 2009).
• Pancreatic beta cell protection: Humanin protected pancreatic beta cells from apoptosis induced by high glucose, free fatty acids, and inflammatory cytokines in cell culture — conditions that mimic the beta cell stress seen in type 2 diabetes (Yen et al., 2013).
• Mitochondrial diabetes: Given humanin's mitochondrial origin, particular interest exists in its role in diabetes caused by mitochondrial mutations (MELAS syndrome and related conditions), though direct therapeutic studies in these populations have not been conducted (Lee et al., 2013).

Aging and Longevity

• Age-related decline: Circulating humanin levels decrease with age in humans. Multiple studies measuring plasma humanin have demonstrated progressive decline starting in middle age (Yen et al., 2013).
• Centenarian studies: Children of centenarians — who have a genetic predisposition to longevity — have been found to have higher circulating humanin levels compared to age-matched controls, suggesting a correlation between humanin and familial longevity (Muzumdar et al., 2009).
• Growth hormone / IGF-1 axis: Humanin levels inversely correlate with GH and IGF-1 levels. Since reduced GH/IGF-1 signaling is associated with extended lifespan in multiple model organisms, this positions humanin as a potential mediator of longevity pathways (Yen et al., 2013).
• Mouse lifespan studies: Long-term HNG administration in mouse models improved multiple age-related parameters including glucose homeostasis, inflammatory markers, and cognitive function, though formal lifespan extension studies remain limited (Yen et al., 2013).

Other Preclinical Findings

• Chemotherapy-induced toxicity: Humanin protected against apoptosis in non-cancerous cells exposed to chemotherapeutic agents, raising interest as a potential adjunct to reduce treatment side effects without compromising anti-tumor efficacy (Yen et al., 2013).
• Retinal degeneration: Humanin protected retinal pigment epithelial cells from oxidative stress-induced apoptosis, with potential relevance to age-related macular degeneration (AMD) (Yen et al., 2013).
• Bone metabolism: Preliminary data suggests humanin influences osteoblast and osteoclast activity, with potential implications for age-related bone loss, though this area is in early stages of investigation (Lee et al., 2013).

Limitations of the Research

• No human intervention trials: Unlike BPC-157, which has at least one Phase 2 trial, humanin has no completed human trials of any phase. All efficacy data is from cell culture and animal models.
• Observational human data only: Human studies have measured endogenous humanin levels and correlated them with health outcomes. Correlation does not establish causation — higher humanin levels in healthy populations may be a marker of health rather than a cause of it.
• Pharmacokinetics unknown in humans: Absorption, distribution, metabolism, and half-life of exogenous humanin in humans have not been characterized.
• Dose translation uncertain: Effective doses in cell culture and animal models have not been validated in human subjects.
• Analog variability: Much research uses HNG or other analogs rather than native humanin. Effects may differ between native peptide and synthetic variants.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA Status

Humanin has no FDA-approved indication. It has not entered the clinical trial process. It is not classified as a drug, dietary supplement, or biologic by the FDA. There are no Investigational New Drug (IND) applications publicly associated with humanin peptide therapy. Any use in humans is entirely experimental and outside of regulatory frameworks.

Research Areas of Interest

The following areas have been explored in preclinical research. None of these represent validated therapeutic applications:

How Humanin Is Currently Accessed

• Research chemical suppliers: Humanin and HNG are available from peptide synthesis companies for research use. Products are labeled "for research purposes only" or "not for human consumption."
• Academic research: Used in laboratory settings for cell culture and animal studies.
• Not available through compounding pharmacies: Unlike some other peptides, humanin has not been widely compounded for clinical use due to the lack of clinical data supporting human administration.

What Humanin Is NOT

• Not a treatment for Alzheimer's disease: While the preclinical data on neuroprotection is the most developed area of humanin research, no human trial has tested whether exogenous humanin prevents or treats Alzheimer's disease.
• Not an anti-aging drug: The correlation between humanin levels and longevity is observational. It has not been demonstrated that administering exogenous humanin extends human lifespan or healthspan.
• Not a performance enhancer: Humanin is not anabolic and has no documented effects on athletic performance.
• Not a replacement for medical care: For any condition in which humanin has been studied preclinically, established treatments exist and should be the first line of management.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Preclinical Doses Used in Research

Preclinical dosing data derived from: Tajima et al., 2005 · Muzumdar et al., 2009 · Muzumdar et al., 2010 · Yen et al., 2013

Reported Research Chemical Dosing

Research chemical dosing is extrapolated from animal studies and has not been validated in human clinical trials. References: Yen et al., 2013 · Muzumdar et al., 2009

Critical Dosing Unknowns

• Human pharmacokinetics: The half-life, bioavailability, and distribution of exogenous humanin/HNG in humans have not been determined.
• Dose-response relationship: No human dose-response data exists. The assumption that animal doses translate to human doses through allometric scaling has not been validated for this peptide.
• Optimal route: Subcutaneous injection is assumed by analogy to other peptides, but the optimal route for human administration has not been established.
• Duration of use: No data exists on appropriate treatment duration, cycling protocols, or long-term use in humans.
• Native vs. analog: HNG is approximately 1,000x more potent than native humanin in vitro. Whether this potency ratio holds for in vivo systemic effects in humans is unknown.

Storage

• Lyophilized powder: Store at -20°C for long-term storage, or 2–8°C (refrigerated) for short-term. Protect from moisture and light.
• Reconstituted solution: Refrigerate at 2–8°C and use within 1–2 weeks. Do not freeze reconstituted peptide. Discard if solution becomes cloudy or discolored.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What the Research Shows

Preclinical Outcomes Summary

Human Observational Data

While no interventional human data exists, several observational studies have measured endogenous humanin levels in human populations:

• Aging: Plasma humanin levels decline progressively with age, with significantly lower levels in elderly subjects compared to young adults (Yen et al., 2013).
• Longevity families: Children of centenarians had higher circulating humanin levels than age-matched controls from non-long-lived families, suggesting a genetic component to humanin expression linked to longevity (Muzumdar et al., 2009).
• GH deficiency: Patients with growth hormone deficiency had higher humanin levels, consistent with the inverse relationship between GH/IGF-1 signaling and humanin (Yen et al., 2013).
• Alzheimer's patients: Some studies have reported reduced humanin levels in CSF and plasma of Alzheimer's disease patients, though results have been inconsistent across studies (Niikura et al., 2011).

Why Human Results Cannot Be Predicted

Extrapolating expected human results from animal data is problematic for several reasons specific to humanin:

• Species differences in endogenous production: The regulation and baseline levels of humanin differ between species, making cross-species dose translation unreliable.
• Unknown human pharmacokinetics: Without data on absorption, half-life, and tissue distribution in humans, predicting therapeutic concentrations and timelines is speculative.
• Endogenous vs. exogenous effects: Observational studies measure endogenous (internally produced) humanin. Whether administering exogenous (external) humanin replicates the protective effects associated with naturally high levels is an open question.
• Biomarker vs. mediator: Elevated humanin in healthy populations may be a biomarker of mitochondrial health rather than a causal mediator of longevity. Supplementing a biomarker does not necessarily replicate the condition it marks.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Animal Safety Data

In preclinical studies, humanin and HNG administration in rodent models has not produced reported significant toxicity or adverse effects at standard research doses. No LD50 has been established. Animal studies spanning days to weeks of administration have not documented organ toxicity, behavioral abnormalities, or mortality attributable to humanin treatment (Yen et al., 2013).

However, the absence of adverse effects in animal models should not be interpreted as evidence of safety in humans. Many compounds are well-tolerated in rodents but produce adverse effects in humans, and conversely. The lack of formal toxicology studies designed specifically to assess safety (as opposed to efficacy studies that note the absence of obvious toxicity) is an important limitation.

Theoretical Risks and Concerns

The Cancer Question

The relationship between humanin and cancer deserves specific attention because humanin's primary mechanism — inhibiting apoptosis — is the same survival strategy that cancer cells use. Several studies have found elevated humanin expression in certain tumor tissues, including glioblastoma and pituitary adenomas. Whether elevated humanin in tumors is causal (promoting tumor survival) or correlative (a stress response to tumor microenvironment) remains debated (Yen et al., 2013).

Until this question is resolved, exogenous humanin administration in individuals with active malignancies, a history of cancer, or elevated cancer risk carries theoretical risk that cannot be quantified. This represents the most important safety consideration for humanin.

Drug Interactions

No formal drug interaction studies have been conducted. Theoretical interactions include:

• Chemotherapy agents: Humanin's anti-apoptotic effects could theoretically reduce the efficacy of chemotherapeutic drugs that kill cancer cells through apoptotic mechanisms.
• Insulin and diabetes medications: Humanin's insulin-sensitizing effects could potentiate the glucose-lowering effects of insulin or oral antidiabetic drugs, increasing hypoglycemia risk.
• Growth hormone therapy: Given the inverse relationship between humanin and GH/IGF-1, co-administration could produce unpredictable endocrine effects.
• Immunosuppressants: Potential interaction through immune-modulating pathways.

Contraindications (Theoretical)

• Active cancer or recent cancer history — due to anti-apoptotic mechanism
• Pregnancy and breastfeeding — no safety data available
• Children — no pediatric data available
• Individuals on chemotherapy — potential reduction of drug efficacy

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Status

Humanin has no FDA classification. Unlike some peptides that have been evaluated under the FDA's bulk drug substance compounding framework (e.g., BPC-157), humanin has not been the subject of any FDA regulatory action — neither approval nor prohibition. This is because it has not been proposed for compounding use or submitted for drug approval by any entity.

The absence of regulatory action does not indicate approval or safety. It reflects the early stage of humanin research — a compound that has not progressed beyond preclinical investigation to the point where regulatory consideration would apply.

Classification Summary

Research Chemical Status

Humanin and HNG are available from peptide synthesis companies as research chemicals. These products are:

• Labeled "for research use only" or "not for human consumption"
• Not manufactured under pharmaceutical GMP standards
• Not subject to FDA oversight for purity, potency, or identity
• Sold to researchers, academic institutions, and individuals who self-identify as researchers
• Variable in quality — certificates of analysis (COAs) may be provided but are not independently verified by regulatory bodies

Legal Considerations

Possessing humanin is not illegal in any known jurisdiction. Purchasing it as a research chemical is legal. However:

• Self-administering a research chemical that is not approved for human use carries inherent legal and medical risk
• Healthcare providers prescribing or administering humanin would be doing so entirely off-label and without regulatory backing — potentially exposing themselves to liability
• No compounding pharmacy framework exists for humanin preparation
• Insurance will not cover any costs associated with humanin

Path to Clinical Use

For humanin to become available as a therapeutic agent, it would need to progress through the standard drug development pipeline:

1. IND application: An Investigational New Drug application would need to be filed with the FDA, supported by preclinical safety and efficacy data.
2. Phase 1 trial: First-in-human safety and pharmacokinetic study.
3. Phase 2 trial: Efficacy and dose-finding study in the target patient population.
4. Phase 3 trial: Large-scale randomized controlled trial confirming efficacy and safety.
5. NDA/BLA submission: Application for marketing approval.

No entity has publicly initiated this process for humanin. The timeline for clinical availability — if it occurs — is unknown and likely measured in years to decades.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Why Humanin Costs More Than Some Peptides

• Synthesis complexity: Humanin is a 24-amino-acid peptide, which is moderately complex to synthesize. HNG requires a specific glycine substitution at position 14, adding to production requirements.
• Low demand: Unlike peptides with broader clinical use (BPC-157, TB-500), humanin has a small market limited primarily to researchers and a niche group of early adopters. Low production volume keeps per-unit costs higher.
• Purity requirements: Effective humanin research requires high-purity peptide (≥95%). Purification adds cost to manufacturing.
• No compounding pharmacy competition: The absence of compounding pharmacy production eliminates a lower-cost sourcing option available for some other peptides.

Insurance Coverage

Humanin is not covered by any insurance plan. As a research chemical with no FDA-approved indication and no IND status, it cannot be prescribed, billed, or reimbursed through any insurance mechanism. All costs are entirely out-of-pocket.

Cost Comparison: Humanin vs. Related Compounds

Cost-Benefit Considerations

Several factors are relevant to the cost-benefit assessment of humanin:

• No proven human efficacy: The $200–$500/month cost purchases a compound with no demonstrated benefits in humans. Preclinical data, however promising, does not guarantee human efficacy.
• Product quality uncertainty: Without pharmaceutical manufacturing standards, the actual peptide content, purity, and bioactivity of research chemical products are uncertain.
• No clinical guidance: The absence of clinical dosing guidelines means there is no way to determine whether a given dose is effective, subtherapeutic, or excessive.
• Alternative uses of funds: For individuals interested in longevity or neuroprotection, established interventions with clinical evidence (exercise, diet, sleep optimization, approved medications where indicated) may offer more reliable returns.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: Humanin is a proven anti-aging treatment.

Answer: Humanin levels correlate with aging and longevity in observational human studies. Children of centenarians have higher levels. Exogenous humanin improved age-related parameters in animal models (Muzumdar et al., 2009). However, no human intervention trial has tested whether administering humanin slows aging, extends lifespan, or improves healthspan. The correlation between endogenous humanin levels and longevity does not establish that supplementing exogenous humanin produces the same effect. Higher humanin may be a biomarker of healthy mitochondria rather than a causal factor in longevity.

Myth: Humanin cures Alzheimer's disease.

Answer: Humanin was discovered through Alzheimer's research and has demonstrated neuroprotective effects against amyloid-beta toxicity in cell culture and transgenic mouse models (Hashimoto et al., 2001; Tajima et al., 2005). These findings have not been tested in human Alzheimer's patients. No clinical trial has evaluated humanin as a treatment for Alzheimer's disease. The gap between protecting cultured neurons from Aβ toxicity and treating a complex neurodegenerative disease in humans is substantial.

Myth: Humanin is just another peptide supplement.

Answer: Humanin is not a supplement. It is not available as a dietary supplement, is not sold through supplement channels, and is not regulated as a supplement. It is a research chemical available from peptide synthesis companies for research purposes. Unlike peptides such as BPC-157 that have been compounded for clinical use, humanin has no clinical use framework. Its evidence base is exclusively preclinical — placing it at an earlier stage of development than most peptides available in clinical contexts.

Myth: Humanin is the same as other mitochondrial supplements like CoQ10 or NAD+.

Answer: Humanin is mechanistically distinct from mitochondrial cofactors. CoQ10 is an electron carrier in the mitochondrial respiratory chain. NAD+ is a coenzyme involved in energy metabolism. Humanin is a signaling peptide — it does not participate in energy production but rather functions as a retrograde signal from mitochondria that activates specific receptor-mediated pathways (STAT3, ERK, BAX inhibition) (Lee et al., 2013). While all three relate to mitochondrial biology, their mechanisms, targets, and clinical evidence bases are entirely different.

Myth: Higher doses of humanin are always better.

Answer: No human dose-response data exists for humanin. In cell culture, humanin's cytoprotective effects are dose-dependent up to a saturation point, after which additional peptide provides no additional benefit. Whether this pattern holds in vivo and in humans is unknown. The assumption that more peptide equals more protection has no empirical support. Additionally, humanin's anti-apoptotic mechanism raises the theoretical concern that excessive or prolonged anti-apoptotic signaling could have unintended consequences, including interference with normal cellular turnover processes (Yen et al., 2013).

Myth: Humanin has been tested in clinical trials.

Answer: No human intervention trial of exogenous humanin has been completed. Human studies of humanin have been observational — measuring endogenous humanin levels in blood or cerebrospinal fluid and correlating them with health outcomes. Observational studies cannot establish causation and are fundamentally different from interventional clinical trials. This is a critical distinction: measuring a natural peptide in the body is not the same as testing whether administering that peptide as a drug produces benefit.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Humanin is a 24-amino-acid mitochondria-derived peptide encoded by the MT-RNR2 gene. It was discovered in 2001 as a neuroprotective factor against amyloid-beta toxicity and was the first identified member of the mitochondria-derived peptide (MDP) class.
• Its primary function is cytoprotection — preventing cell death through BAX inhibition, IGFBP-3 binding, STAT3 activation, and receptor-mediated signaling via FPRL1 and the CNTFR/WSX-1/gp130 trimeric complex.
• Preclinical research spans neurodegeneration, cardiovascular disease, metabolic syndrome, and aging. HNG (the potent S14G analog) has shown protective effects in Alzheimer's mouse models, cardiac ischemia models, diet-induced obesity models, and atherosclerosis models.
• No human intervention trials have been completed. All efficacy data is from cell culture and animal models. Human data is limited to observational studies measuring endogenous humanin levels.
• Circulating humanin levels decline with age and are higher in the offspring of centenarians, suggesting a correlation with longevity — though causation has not been established.
• The most significant theoretical safety concern is cancer risk — humanin's anti-apoptotic mechanism could theoretically support tumor cell survival. This concern is unresolved.
• Humanin is available only as a research chemical. It has no FDA approval, no IND status, no compounding pharmacy availability, and no insurance coverage.
• Cost ranges from $200–$500/month for HNG from research chemical suppliers. All costs are out-of-pocket for an unproven compound.

The Bottom Line

Humanin represents a scientifically significant discovery in mitochondrial biology with a compelling preclinical profile across multiple disease models. It occupies an earlier stage of development than most peptides discussed in clinical longevity and regenerative medicine contexts. The gap between its preclinical promise and clinical validation remains wide — no human trial has tested whether exogenous humanin administration produces any of the benefits observed in cell culture and animal models. Individuals considering humanin should weigh the complete absence of human efficacy and safety data against the cost and theoretical risks.

Questions to Ask a Provider

• Given that no human trials exist for humanin, what is the evidence basis for considering it?
• How does the theoretical cancer risk from anti-apoptotic signaling affect the risk-benefit assessment in my case?
• What monitoring would be appropriate if using a research chemical with no established safety profile?
• Are there established interventions with clinical evidence that address the same goals?
• How would you assess the quality and purity of a research chemical product?
• What is the realistic expectation for benefit from a compound without human validation?

Sources & Further Reading

Discovery & Foundational Research

• Hashimoto et al. (2001) — "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ" — PNAS
• Lee et al. (2013) — "The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity" — Aging Cell

Comprehensive Reviews

• Yen et al. (2013) — "The emerging role of the mitochondrial-derived peptide humanin in stress resistance" — Journal of Molecular Endocrinology
• Niikura et al. (2011) — "Humanin: neuroprotection and beyond" — Expert Opinion on Biological Therapy

Mechanism of Action

• Guo et al. (2003) — "Humanin peptide suppresses apoptosis by interfering with BAX activation" — Nature
• Ikonen et al. (2003) — "Interaction between the Alzheimer's survival peptide humanin and IGFBP-3" — PNAS
• Ying et al. (2004) — "Humanin, a newly identified neuroprotective factor, uses the G protein-coupled formylpeptide receptor-like-1 as a functional receptor" — Journal of Immunology
• Hashimoto et al. (2009) — "Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults" — Neuroendocrinology

Neurodegeneration & Neuroprotection

• Tajima et al. (2005) — "Evidence for in vivo production of humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults" — Neuroscience Letters
• Niikura et al. (2011) — "Humanin and neuroprotection" — Expert Opinion on Biological Therapy

Cardiovascular Research

• Muzumdar et al. (2010) — "Humanin protects the heart against myocardial ischemia-reperfusion injury" — American Journal of Physiology
• Oh et al. (2011) — "Humanin preserves endothelial function and prevents atherosclerotic plaque progression in hypercholesterolemic ApoE deficient mice" — Atherosclerosis

Metabolic Effects & Aging

• Muzumdar et al. (2009) — "Humanin: a novel central regulator of peripheral insulin action" — Peptides

Regulatory References

• FDA: IND Application Process
• WADA: Prohibited List (current year)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.